Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation

Clinical Transplantation

Volumn 23, Issue 4, 2009, Pages 511-518

  Åsberg, Anders ^a,b   Midtvedt, Karsten ^a   Voytovich, Monica H ^a   Line, Pål Dag ^a   Narverud, Janicke ^a   Reisæter, Anna V ^a   Mørkrid, Lars ^a   Jenssen, Trond ^a   Hartmann, Anders ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Calcineurin inhibitor; Endothelial function; Insulin secretion; Insulin sensitivity; Kidney transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; ENDOTHELIN 1; GENZYME; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; PREDNISOLONE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LASER DOPPLER FLOWMETRY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; TREATMENT DURATION; VASCULAR ENDOTHELIUM;

ADULT; AGED; BLOOD GLUCOSE; CALCINEURIN; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; KIDNEY TRANSPLANTATION; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; SKIN; TIME;

EID: 68349154454     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.00962.x     Document Type: Article

References (33)

1. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003: 3: 178.
2. Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis 2004: 43: 953.
3. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care 2002: 25: 583.
4. Depczynski B, Daly B, Campbell LV, Chisholm DJ, Keogh A. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med 2000: 17: 15.
5. Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999: 34: 1.
6. Matsumoto K, Yamasaki H, Akazawa S et al. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab 1996: 81: 2621.
7. Midtvedt K, Hjelmesaeth J, Hartmann A et al. Insulin resistance after renal transplantation: The effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004: 15: 3233.
8. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002: 13: 221.
9. Drachenberg CB, Klassen DK, Weir MR et al. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999: 68: 396.
10. Nielsen JH, Mandrup-Poulsen T, Nerup J. Direct effects of cyclosporin A on human pancreatic beta-cells. Diabetes 1986: 35: 1049.
11. Andersson A, Borg H, Hallberg A, Hellerstrom C, Sandler S, Schnell A. Long-term effects of cyclosporin A on cultured mouse pancreatic islets. Diabetologia 1984: 27(Suppl.): 66.
12. Polastri L, Galbiati F, Bertuzzi F et al. Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. Acta Diabetol 2002: 39: 229.
13. Menegazzo LA, Ursich MJ, Fukui RT et al. Mechanism of the diabetogenic action of cyclosporin A. Horm Metab Res 1998: 30: 663.
14. Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab 2001: 3: 393.
15. van Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrol 2001: 12: 583.
16. Hjelmesaeth J, Hagen LT, Åsberg A et al. The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man. Nephrol Dial Transplant 2007: 22: 1743.
17. Åsberg A, Midtvedt K, Line PD et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006: 82: 62.
18. Hjelmesaeth J, Midtvedt K, Jenssen T, Hartmann A. Insulin resistance after renal transplantation: Impact of immunosuppressive and antihypertensive therapy. Diabetes Care 2001: 24: 2121.
19. Stumvoll M, Mitrakou A, Pimenta W et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000: 23: 295.
20. Åsberg A, Berg KJ, Hartmann A. Each administration of cyclosporin A enhances skin microvascular reactivity in renal transplant recipients. Microvasc Res 2000: 60: 81.
21. Voytovich MH, Asberg A, Hjelmesaeth J, Jenssen T, Hartmann A. Association between insulin resistance and endothelial dysfunction in renal transplant recipients. Clin Transplant 2006: 20: 195.
22. Mandla R, Line PD, Midtvedt K, Bergan S. Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. Ther Drug Monit 2003: 25: 407.
23. Åsberg A, Holm T, Vassbotn T, Andreassen AK, Hartmann A. Nonspecific microvascular vasodilation during iontophoresis is attenuated by application of hyperosmolar saline. Microvasc Res 1999: 58: 41.
24. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: A critical evaluation. Clin Chem 1995: 41: 892.
25. Sato T, Inagaki A, Uchida K et al. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation 2003: 76: 1320.
26. Caumo A, Luzi L. First-phase insulin secretion: Does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab 2004: 287: E371.
27. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 1997: 40: 1439.
28. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: Old hormones, new targets. Clin Sci (Lond) 1999: 96: 513.
29. Ikeuchi M, Kida K, Goto Y, Kaino Y, Matsuda H. In vivo and in vitro effects of cyclosporin A on glucose transport by soleus muscles of mice. Biochem Pharmacol 1992: 43: 1459.
30. Kutkuhn B, Hollenbeck M, Heering P et al. Development of insulin resistance and elevated blood pressure during therapy with cyclosporine A. Blood Press 1997: 6: 13.
31. Åsberg A, Hjelmesaeth J, Voytovich MH, Hartmann A. Endothelial function in renal transplant recipients is associated with circulating nitric oxide, ACE inhibitor use and time after transplantation. Vasc Dis Prev 2006: 3: 229.
32. Åsberg A, Hartmann A, Fjeldså E, Holdaas H. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant 2001: 16: 1920.
33. Åsberg A, Hartmann A, Fjeldså E, Holdaas H. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant 2001: 16: 1920.